-
The American Journal of Psychiatry Sep 1995
Topics: Adult; Bipolar Disorder; Dose-Response Relationship, Drug; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine
PubMed: 7653703
DOI: 10.1176/ajp.152.9.1399b -
Connecticut Medicine Sep 1993The introduction of the selective serotonin reuptake inhibitors (SSRIs) over the past several years has made a major impact on the treatment of depression and other... (Review)
Review
The introduction of the selective serotonin reuptake inhibitors (SSRIs) over the past several years has made a major impact on the treatment of depression and other neuropsychiatric disorders. Agents in this heterogeneous group of compounds are generally better tolerated and less toxic than the tricyclic antidepressants (TCAs), which they have in many respects superseded. This review summarizes available data on paroxetine, the newest SSRI to receive approval for the treatment of depression.
Topics: Depressive Disorder; Drug Interactions; Humans; Paroxetine
PubMed: 8252846
DOI: No ID Found -
American Journal of Therapeutics 2020
Topics: Drug Repositioning; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors
PubMed: 32902939
DOI: 10.1097/MJT.0000000000001011 -
BMC Medicine Aug 2005Inclusion of unpublished data on the effects of antidepressants on children has suggested unfavourable risk-benefit profiles for some of the drugs. Recent meta-analyses... (Review)
Review
BACKGROUND
Inclusion of unpublished data on the effects of antidepressants on children has suggested unfavourable risk-benefit profiles for some of the drugs. Recent meta-analyses of studies on adults have indicated similar effects. We obtained unpublished data for paroxetine that have so far not been included in these analyses.
METHODS
The documentation for drug registration contained 16 studies in which paroxetine had been randomised against placebo. We registered the number of suicides, suicide attempts and ideation. We corrected for duration of medication and placebo treatment and used a standard Bayesian statistical approach with varying priors.
RESULTS
There were 7 suicide attempts in patients on the drug and 1 in a patient on placebo. We found that the probability of increased intensity of suicide attempts per year in adults taking paroxetine was 0.90 with a "pessimistic" prior, and somewhat less with two more neutral priors.
CONCLUSION
Our findings support the results of recent meta-analyses. Patients and doctors should be warned that the increased suicidal activity observed in children and adolescents taking certain antidepressant drugs may also be present in adults.
Topics: Adult; Bayes Theorem; Depression; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted
PubMed: 16115311
DOI: 10.1186/1741-7015-3-14 -
International Clinical... Jan 1997All 10 placebo-controlled studies of the psychomotor effects of paroxetine are reviewed. The total number of subjects is 195. The majority of studies show little or no... (Review)
Review
All 10 placebo-controlled studies of the psychomotor effects of paroxetine are reviewed. The total number of subjects is 195. The majority of studies show little or no effect of paroxetine on psychomotor function. No adverse effects are apparent at the dose of 20 mg/day, although minor impairments can be identified at 40 mg/day. An overview of the data indicates that at the standard therapeutic dose of 20 mg/day, paroxetine has no psychomotor or behavioural toxicity.
Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Humans; Paroxetine; Psychomotor Performance
PubMed: 9179629
DOI: 10.1097/00004850-199701000-00002 -
The Journal of Urology Feb 2011
Topics: Humans; Male; Paroxetine; Spermatozoa
PubMed: 22088649
DOI: 10.1016/S0022-5347(11)60139-0 -
The Journal of Clinical Psychiatry Feb 1995
Topics: Aged; Basal Ganglia Diseases; Delusions; Depressive Disorder; Drug Interactions; Female; Humans; Molindone; Parkinson Disease, Secondary; Paroxetine
PubMed: 7852260
DOI: No ID Found -
International Clinical... Jun 1994In contrast to tricyclic antidepressants (TCAs), the selective serotonin reuptake inhibitors (SSRIs) have a high affinity for the serotonin uptake site with little or no... (Comparative Study)
Comparative Study Review
In contrast to tricyclic antidepressants (TCAs), the selective serotonin reuptake inhibitors (SSRIs) have a high affinity for the serotonin uptake site with little or no affinity for alpha-adrenergic, cholinergic or histaminic receptors. SSRIs, again in contrast to TCAs, do not slow intracardiac conduction. These differences between TCAs and SSRIs are important in terms of both discomforting and more serious adverse effects. Despite their more focused effects, the SSRIs are as effective as TCAs in treating major depression. The SSRIs have similar properties in terms of their pharmacodynamics, but important differences in terms of pharmacokinetics and their effects on hepatic function. Sertraline, and the starting dose of paroxetine have an elimination half-life (t1/2) of approximately 24 h. However, the half-life of paroxetine, but not of sertraline, becomes longer at higher doses due to paroxetine's inhibition of its own clearance. At t1/2 of 24 h makes once-daily dosing feasible and allows for new steady-state concentrations and wash-out within a reasonable time after dose adjustment. Fluoxetine has a t1/2 of 2-4 days and has an active metabolite with a t1/2 of 7-15 days. Such a half-life makes dose titration more difficult, and can result in prolonged effects even after dose reduction or drug discontinuation. Sertraline has dose-proportional changes in plasma concentrations, in contrast to fluoxetine and paroxetine. Thus, dose increases with fluoxetine and paroxetine produce greater than expected changes in plasma drug concentration, and hence, in concentration-dependent effects.(ABSTRACT TRUNCATED AT 250 WORDS)
Topics: 1-Naphthylamine; Depressive Disorder; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Half-Life; Humans; Metabolic Clearance Rate; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline
PubMed: 7963446
DOI: 10.1142/9789814440912_0082 -
International Clinical... Jun 1992The classical tricyclic antidepressant drugs effectively relieve the symptoms of depression, but they have the potential to be severely toxic to the cardiovascular... (Clinical Trial)
Clinical Trial Randomized Controlled Trial Review
The classical tricyclic antidepressant drugs effectively relieve the symptoms of depression, but they have the potential to be severely toxic to the cardiovascular system--including postural hypotension after therapeutic doses and lethal arrhythmias after overdosage. Paroxetine has been shown to be of similar efficacy to the tricyclic antidepressants but has lower cardiovascular toxicity in animal models and has no effects on heart rate, blood pressure or the electrocardiogram in healthy men receiving single 20-40 mg doses. The results of two contrasting studies in depressive patients and healthy men provide strong evidence that therapeutic doses of paroxetine lack any important haemodynamic or electrophysiological effects.
Topics: Blood Pressure; Cardiovascular System; Depressive Disorder; Female; Heart Rate; Humans; Male; Paroxetine
PubMed: 1431013
DOI: No ID Found -
International Clinical... Jun 1992Studies on the behavioural effects of paroxetine on healthy young volunteers, elderly volunteers, and patients suffering from major depressive illness failed to show any... (Clinical Trial)
Clinical Trial Randomized Controlled Trial Review
Studies on the behavioural effects of paroxetine on healthy young volunteers, elderly volunteers, and patients suffering from major depressive illness failed to show any evidence of detrimental effects on a battery of objective and subjective measures even when alcohol was taken. In contrast, the chosen verum, amitriptyline or lorazepam, produced significant impairment. The study on depressed patients showed improvement in cognitive functions among the paroxetine group from the start, whereas these functions were, initially, significantly impaired in the dothiepin group. Moreover, the Leeds Sleep Evaluation Questionnaire indicated that dothiepin produced, with respect to paroxetine, a significantly poorer quality of sleep.
Topics: Adult; Aged; Aging; Depressive Disorder; Female; Humans; Male; Middle Aged; Paroxetine; Psychomotor Performance
PubMed: 1431014
DOI: 10.1097/00004850-199206004-00012